Literature DB >> 14694118

Potential selection of LMP1 variants in nasopharyngeal carcinoma.

Rachel H Edwards1, Diane Sitki-Green, Dominic T Moore, Nancy Raab-Traub.   

Abstract

Seven distinct sequence variants of the Epstein-Barr virus latent membrane protein 1 (LMP1) have been identified by distinguishing amino acid changes in the carboxy-terminal domain. In this study the transmembrane domains are shown to segregate identically with the distinct carboxy-terminal amino acid sequences. Since strains of LMP1 have been shown to differ in abundance between blood and throat washes, nasopharyngeal carcinomas (NPCs) from areas of endemicity and nonendemicity with matching blood were analyzed by using a heteroduplex tracking assay to distinguish LMP1 variants. Striking differences were found between the compartments with the Ch1 strain prevalent in the NPCs from areas of endemicity and nonendemicity and the B958 strain prevalent in the blood of the endemic samples, whereas multiple strains of LMP1 were prevalent in the blood of the nonendemic samples. The possible selection against the B958 strain appearing in the tumor was highly significant (P < 0.0001). Sequence analysis of the full-length LMP1 variants revealed changes in many of the known and computer-predicted HLA-restricted epitopes with changes in key positions in multiple, potential epitopes for the specific HLA of the patients. These amino acid substitutions at key positions in the LMP1 epitopes may result in a reduced cytotoxic-T-lymphocyte response. These data indicate that strains with specific variants of LMP1 are more likely to be found in NPC. The predominance of specific LMP1 variants in NPC could reflect differences in the biologic or molecular properties of the distinct forms of LMP1 or possible immune selection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694118      PMCID: PMC368819          DOI: 10.1128/jvi.78.2.868-881.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  89 in total

1.  Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.

Authors:  G Henle; W Henle
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

2.  Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1.

Authors:  Neil A Marshall; Mark A Vickers; Robert N Barker
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

3.  An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Authors:  S Gottschalk; C Y Ng; M Perez; C A Smith; C Sample; M K Brenner; H E Heslop; C M Rooney
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

Review 4.  Nasopharyngeal carcinoma (NPC).

Authors:  J H Ho
Journal:  Adv Cancer Res       Date:  1972       Impact factor: 6.242

5.  Prevalence, incidence and persistence of EB virus antibody in young adults.

Authors:  J C Niederman; A S Evans; L Subrahmanyan; R W McCollum
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

Review 6.  Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows
Journal:  Annu Rev Microbiol       Date:  2000       Impact factor: 15.500

7.  Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2.

Authors:  Georg Lautscham; Tracey Haigh; Sabine Mayrhofer; Graham Taylor; Debbie Croom-Carter; Alison Leese; Stephan Gadola; Vincenzo Cerundolo; Alan Rickinson; Neil Blake
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Localization of the Epstein-Barr virus protein LMP 1 to exosomes.

Authors:  James Flanagan; Jaap Middeldorp; Tom Sculley
Journal:  J Gen Virol       Date:  2003-07       Impact factor: 3.891

9.  Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells.

Authors:  Kiyotaka Kuzushima; Naomi Hayashi; Ayumi Kudoh; Yoshiki Akatsuka; Kunio Tsujimura; Yasuo Morishima; Tatsuya Tsurumi
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

10.  Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions.

Authors:  Jaikumar Duraiswamy; Jacqueline M Burrows; Mandvi Bharadwaj; Scott R Burrows; Leanne Cooper; Nattiya Pimtanothai; Rajiv Khanna
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  39 in total

1.  LMP1 strain variants: biological and molecular properties.

Authors:  Bernardo A Mainou; Nancy Raab-Traub
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma.

Authors:  Masayoshi Nagamine; Miki Takahara; Kan Kishibe; Toshihiro Nagato; Hideyuki Ishii; Nobuyuki Bandoh; Takeshi Ogino; Yasuaki Harabuchi
Journal:  Virus Genes       Date:  2006-08-18       Impact factor: 2.332

3.  Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting.

Authors:  Margaret L Gulley; Hongxin Fan; Sandra H Elmore
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

4.  Modulation of LMP1 protein expression by EBV-encoded microRNAs.

Authors:  Angela Kwok Fung Lo; Ka Fai To; Kwok Wai Lo; Raymond Wai Ming Lung; Jan Wai Ying Hui; Gangling Liao; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

5.  Comparative analysis of oncogenic properties and nuclear factor-kappaB activity of latent membrane protein 1 natural variants from Hodgkin's lymphoma's Reed-Sternberg cells and normal B-lymphocytes.

Authors:  Nathalie Faumont; Aurélie Chanut; Alan Benard; Nadine Cogne; Georges Delsol; Jean Feuillard; Fabienne Meggetto
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

6.  Modified Anoikis Assay That Functionally Segregates Epstein-Barr Virus LMP1 Strains into Two Groups.

Authors:  Laura R Wasil; Kathy H Y Shair
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

7.  Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology.

Authors:  Pan Liu; Xiaodong Fang; Zizhen Feng; Yun-Miao Guo; Rou-Jun Peng; Tengfei Liu; Zhiyong Huang; Yue Feng; Xiaoqing Sun; Zhiqiang Xiong; Xiaosen Guo; Sha-Sha Pang; Bo Wang; Xiaojuan Lv; Fu-Tuo Feng; Da-Jiang Li; Li-Zhen Chen; Qi-Sheng Feng; Wen-Lin Huang; Mu-Sheng Zeng; Jin-Xin Bei; Yong Zhang; Yi-Xin Zeng
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

8.  Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient.

Authors:  Mu-Sheng Zeng; Da-Jiang Li; Qing-Lun Liu; Li-Bing Song; Man-Zhi Li; Ru-Hua Zhang; Xing-Juan Yu; Hui-Min Wang; Ingemar Ernberg; Yi-Xin Zeng
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

9.  Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.

Authors:  Mark D Sides; Gregory J Block; Bin Shan; Kyle C Esteves; Zhen Lin; Erik K Flemington; Joseph A Lasky
Journal:  Virology       Date:  2011-05-24       Impact factor: 3.616

Review 10.  The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk.

Authors:  Elham Hassen; Ghandri Nahla; Noureddine Bouaouina; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2009-05-17       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.